NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

H. Lundbeck A/S (F: LDB)

 
LDB Technical Analysis
5
As on 13th Jun 2022 LDB STOCK Price closed @ 1.71 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 26.62 & Strong Sell for SHORT-TERM with Stoploss of 31.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

LDBSTOCK Price

Open 1.74 Change Price %
High 1.74 1 Day -21.31 -92.57
Low 1.66 1 Week -20.61 -92.34
Close 1.71 1 Month -19.95 -92.11
Volume 9000 1 Year -24.89 -93.57
52 Week High 34.37 | 52 Week Low 19.59
 
F Germany Most Active Stocks
IMU 0.10 %
IMU 0.10 %
IMU 0.10 %
IMU 0.10 %
IMU 0.10 %
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
D05 38.15 %
 
F Germany Top Gainers Stocks
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
8S3B 1.73 620.83%
8S3B 1.73 620.83%
SY7P 0.07 600.00%
P9F1 1.75 326.83%
 
F Germany Top Losers Stocks
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
AETG 0.25 -91.61%
AETG 0.25 -91.61%
 
 
LDB
Daily Charts
LDB
Intraday Charts
Whats New @
Bazaartrend
LDB
Free Analysis
 
LDB Important Levels Intraday
RESISTANCE1.86
RESISTANCE1.81
RESISTANCE1.78
RESISTANCE1.75
SUPPORT1.67
SUPPORT1.64
SUPPORT1.61
SUPPORT1.56
 
LDB Forecast July 2024
4th UP Forecast13.54
3rd UP Forecast9.75
2nd UP Forecast7.4
1st UP Forecast5.06
1st DOWN Forecast-1.64
2nd DOWN Forecast-3.98
3rd DOWN Forecast-6.33
4th DOWN Forecast-10.12
 
LDB Weekly Forecast
4th UP Forecast8.90
3rd UP Forecast6.59
2nd UP Forecast5.17
1st UP Forecast3.74
1st DOWN Forecast-0.32
2nd DOWN Forecast-1.75
3rd DOWN Forecast-3.17
4th DOWN Forecast-5.48
 
LDB Forecast2024
4th UP Forecast65.3
3rd UP Forecast44.91
2nd UP Forecast32.3
1st UP Forecast19.7
1st DOWN Forecast-16.28
2nd DOWN Forecast-28.88
3rd DOWN Forecast-41.49
4th DOWN Forecast-61.88
 
 
LDB Other Details
Segment EQ
Market Capital 4770306560.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
LDB Address
LDB
 
LDB Latest News
 
Your Comments and Response on H. Lundbeck A/S
 
LDB Business Profile
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark. Address: Ottiliavej 9, Valby, Denmark, 2500
 
2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service